Ventus Therapeutics

About Ventus Therapeutics

Ventus Therapeutics is a biopharmaceutical company focused on creating exceptional medicines using their proprietary ReSOLVE platform. Their mission is to address biologically validated drug targets previously considered undruggable and to improve therapies where current options are insufficient for patients.

Products & Services

VENT-02:A brain-penetrant NLRP3 inhibitor currently in a Phase 2 trial for Parkinson's disease.

VENT-03:A first-in-class cGAS inhibitor expected to enter Phase 2 development for lupus in 2025.

Pipeline of Therapeutics:A robust pipeline of differentiated therapeutics targeting challenging drug targets.

ReSOLVE Platform:A powerful drug discovery platform combining AI/ML, protein science, structural biology, and biophysics to enhance the speed and accuracy of small-molecule drug discovery.

Specialties

Small-molecule drug discovery Structural immunology AI/ML in drug development Protein science Structural biology Biophysics Targeting undruggable drug targets

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 150000 MR: - FA: $150,000 FAN: 150000	D: 2023-04-20 FD: 2023-04-20	1 investors

Grant Latest

2023-04-20

$150K

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Laurent Audoly

Serial biotech entrepreneur and senior executive in the biotech/pharma industry

C

Christopher Bayly

Head of Affinity Group at OpenEye Scientific Software

J

John Chodera

Associate Member at Sloan Kettering Institute for Cancer Research

T

Tom Kurtzman

Professor

D

Dennis Zaller

Chief Scientific Officer

P

Peter Kollman

View 30 more team members with Pro

Unlock Full Team Directory

Recent News